Abdulkareem Al-Garni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdulkareem Al-Garni has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Farooq Sabar
Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan
2 shared publications - Zafar Iqbal
Genomic & Experimental Medicine Group (GEM) & Quality Assurance and Accreditation Unit (QAAA), CLSP, College of Applied Medical Sciences (CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, Al-Ahsa, Saudi Arabia; Division of Adult Oncology, Department of Medicine, King Abdulaziz Hospital, Al-Ahsa, Saudi Arabia; Centers of Excellence in Precision Medicine, Oncology and Biotechnology, INNOVACORE Center for Research & Biotechnology, San Antonio, Texas, USA, Saudi Arabia
2 shared publications - Abdullah Alruwaili
Emergency Medical Services, College of Applied Medical Sciences Al Ahsa 31982 King Saud Bin Abdulaziz University for Health Sciences
1 shared publication - Adnan Iqbal
Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan
1 shared publication - Aftab Ahmed Jalbani
King Abdulaziz Hospital; National Guard Health Affairs, Saudi Arabia
1 shared publication - Amer Mahmood
Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 24 April 2026
- Published by MDPI AG in Preprints.org
Dominant COSMIC Mutational Signatures and Unsupervised Machine Learning Define Mechanism-Based Therapeutic Stratification in Blast-Crisis CML: Implications in Precision Medicine of Relapsed and Refractory Cancers
Background/Objectives: Blast-crisis chronic myeloid leukemia (BC-CML) represents a genomically unstable, therapeutically refractory phase driven by clonal evolution beyond BCR::ABL1 dependence. Clinical outcomes remain poor, with median survival under one year. Mutation-level analyses inadequately resolve biological heterogeneity or inform rational patient-specific therapy. We therefore implemented a mutational process–anchored framework integrating genomics, machine learning (ML), and artificial intelligence (AI)–guided drug prioritization at single-patient resolution. Methods: Whole-exome sequencing, COSMIC mutational signature deconvolution, unsupervised ML clustering, and AI-guided pharmacogenomic prioritization were applied to 224 patients with CML (190 chronic phase, 15 accelerated phase, 19 blast crisis) and 19 healthy controls. Results: Mutation burden increased significantly with disease progression, and blast crisis exhibited complex co-mutation architectures involving TP53, BRCA2, IDH1/2, DNMT3A, JAK2, and CSF3R. While gene-level patterns were heterogeneous, dominant mutational processes converged across cases. COSMIC signature extraction stratified BC-CML into three biologically coherent clusters: homologous recombination deficiency/genomic instability (Signatures 3/5), epigenetic–metabolic dysregulation (Signatures 1/2), and oxidative stress–associated cytokine signaling mutagenesis (Signatures 13/18). These process-defined states mechanistically link DNA repair failure, chromatin remodeling, and inflammatory signaling to blast transformation. Integration with an AI-guided pharmacogenomic framework translated signature biology into rational, cluster-specific therapeutic prioritization, including PARP inhibition, IDH targeting, CDK4/6 blockade, JAK pathway inhibition, and redox-modulating strategies. Dominant signature resolution reduced multidrug ambiguity and supported single-patient therapeutic parsimony. External concordance assessment across independent pharmacogenomic datasets supported predicted vulnerabilities. Conclusions: This study establishes a mechanistically interpretable, process-anchored precision oncology framework for BC-CML linking genomic architecture to actionable therapeutic decision-making warranting clinical validation. The approach can further be implemented for AL-AI-prioritized precision treatment of other relapsed, refractory and metastatic cancers.
- 24 April 2026
- Published by MDPI AG in Preprints.org
Open AccessDominant COSMIC Mutational Signatures and Unsupervised Machine Learning Define Mechanism-Based Therapeutic Stratification in Blast-Crisis CML: Implications in Precision Medicine of Relapsed and Refractory Cancers
Background/Objectives: Blast-crisis chronic myeloid leukemia (BC-CML) represents a genomically unstable, therapeutically refractory phase driven by clonal evolution beyond BCR::ABL1 dependence. Clinical outcomes remain poor, with median survival under one year. Mutation-level analyses inadequately resolve biological heterogeneity or inform rational patient-specific therapy. We therefore implemented a mutational process–anchored framework integrating genomics, machine learning (ML), and artificial intelligence (AI)–guided drug prioritization at single-patient resolution. Methods: Whole-exome sequencing, COSMIC mutational signature deconvolution, unsupervised ML clustering, and AI-guided pharmacogenomic prioritization were applied to 224 patients with CML (190 chronic phase, 15 accelerated phase, 19 blast crisis) and 19 healthy controls. Results: Mutation burden increased significantly with disease progression, and blast crisis exhibited complex co-mutation architectures involving TP53, BRCA2, IDH1/2, DNMT3A, JAK2, and CSF3R. While gene-level patterns were heterogeneous, dominant mutational processes converged across cases. COSMIC signature extraction stratified BC-CML into three biologically coherent clusters: homologous recombination deficiency/genomic instability (Signatures 3/5), epigenetic–metabolic dysregulation (Signatures 1/2), and oxidative stress–associated cytokine signaling mutagenesis (Signatures 13/18). These process-defined states mechanistically link DNA repair failure, chromatin remodeling, and inflammatory signaling to blast transformation. Integration with an AI-guided pharmacogenomic framework translated signature biology into rational, cluster-specific therapeutic prioritization, including PARP inhibition, IDH targeting, CDK4/6 blockade, JAK pathway inhibition, and redox-modulating strategies. Dominant signature resolution reduced multidrug ambiguity and supported single-patient therapeutic parsimony. External concordance assessment across independent pharmacogenomic datasets supported predicted vulnerabilities. Conclusions: This study establishes a mechanistically interpretable, process-anchored precision oncology framework for BC-CML linking genomic architecture to actionable therapeutic decision-making warranting clinical validation. The approach can further be implemented for AL-AI-prioritized precision treatment of other relapsed, refractory and metastatic cancers.
- Open Access
- 9 August 2024
- Published by MDPI AG in Preprints.org
Genotype-Phenotype Correlations in Inherited Cardiomyopathies, Their Role in Clinical Decision-Making and Implications in Personalized Cardiac Medicine in Multi-omics as Well as Disease Modelling Eras
Inherited cardiomyopathies are a diverse group of heart muscle diseases caused by genetic mutations that result in structural and functional abnormalities of the myocardium. Understanding genotype-phenotype correlations in these conditions is vital for personalized cardiac medicine, enabling targeted therapeutic strategies and predictive diagnostics. This review explores the major types of inherited cardiomyopathies—hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM)—and provides detailed insights into how different genetic mutations manifest as clinical features. The integration of multi-omics approaches and advanced disease modeling techniques has enhanced our ability to dissect these correlations. The review also discusses the implications of these findings for personalized medicine, including tailored therapeutic strategies, predictive diagnostics, and future research directions.
- 9 August 2024
- Published by MDPI AG in Preprints.org
Open AccessGenotype-Phenotype Correlations in Inherited Cardiomyopathies, Their Role in Clinical Decision-Making and Implications in Personalized Cardiac Medicine in Multi-omics as Well as Disease Modelling Eras
Inherited cardiomyopathies are a diverse group of heart muscle diseases caused by genetic mutations that result in structural and functional abnormalities of the myocardium. Understanding genotype-phenotype correlations in these conditions is vital for personalized cardiac medicine, enabling targeted therapeutic strategies and predictive diagnostics. This review explores the major types of inherited cardiomyopathies—hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM)—and provides detailed insights into how different genetic mutations manifest as clinical features. The integration of multi-omics approaches and advanced disease modeling techniques has enhanced our ability to dissect these correlations. The review also discusses the implications of these findings for personalized medicine, including tailored therapeutic strategies, predictive diagnostics, and future research directions.